Pneumonia is referred to as inflammatory, diseased condition of the lungs, which affects the alveoli of the lungs. Symptoms of pneumonia include chest pain, dry cough, trouble in breathing, and fever. Acquired pneumonia and health care-associated pneumonia are two types of pneumonia. Pneumonia affects over 450 million people across the globe and results in four million deaths every year. The global pneumonia therapeutics market is projected to expand at a significant pace during the forecast period, due to increase in the number of cases of pneumonia and advancement in treatments. Moreover, growing awareness about pneumonia treatment among patients, rising demand for treatment, increasing incidence of pneumonia, and improvement in diagnosis methods are promoting the growth of the global pneumonia therapeutics market.
Currently, the pneumonia therapeutics market is witnessing extensive research and development activities and a significant number of new product launches. This encourages manufacturers to cater to the increasing demand from customers. The global pneumonia therapeutics market is consolidated, with the top players such as Sanofi, Eli Lilly, AstraZeneca, Merck & Co. Novartis, GlaxoSmithCline, Pfizer, and Baxter International Inc. accounting for a major share of the market. Most of the companies are taking considerable research efforts toward development of novel drugs and diagnostic techniques and offering substantial support in terms of funding. This has fueled the market. Furthermore, significant unmet needs for curative treatment of pneumonia are likely to drive the market. The pneumonia therapeutics market in developing economies in Asia is likely to expand, as the prevalence of pneumonia is higher in these countries. Pneumonia-related fatalities in children are mostly preventable through proper education and awareness and timely treatment. Thus, rising awareness about treating pneumonia in children could be a growth opportunity for manufacturers of pneumonia drugs. Rapid urbanization, risen levels of air pollution, changes in lifestyle, and increased smoking population have resulted in high occurrence of asthma and pneumonia in people staying in urban areas, thereby fueling the global pneumonia therapeutics market.
The global pneumonia therapeutics market can be segmented based on therapeutics, distribution channel, and region. Based on therapeutics, the market has been classified into prevention vaccines and treatment drugs. Usually, treatment drugs include antibiotics such as penicillin, cephalosporins, fluoroquinolones, tetracyclines, amoxicillin, vancomycin, and clavulanic acid. Penicillin was widely used to treat pneumonia caused by the bacterium Pneumococcal pneumonia. However, wide use of a broad spectrum of antibiotics has resulted in significant drug resistance. Penicillin is still used, but only after confirming the sensitivity of the bacterium toward this antibiotic. Vaccination is also preferred to prevent viral and certain bacterial pneumonias, both in adults and children. The Center for Disease Control and Prevention (CDC) recommends that every adult be vaccinated once a year. Based on distribution channel, the pneumonia therapeutics market can be divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment holds a major market share and is likely to sustain its leading position throughout the forecast period.
Based on geography, the global pneumonia therapeutics market has been segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominates the global market and the trend is expected to continue during the forecast period. This is attributable to rising awareness about pneumonia and costly pneumonia management. Asia Pacific is expected to hold the second-largest share of the global pneumonia therapeutics market during the forecast period, due to high incidence of pneumonia in countries such as China and India. China is estimated to account for a leading share of the pneumonia therapeutics market in Asia Pacific from 2017 to 2025, owing to factors such as improvement in the diagnosis rate, rapidly aging population, and high levels of pollution.
The number of players operating in the global pneumonia therapeutics market is limited; however, several companies are interested to invest in the market, due to increasing demand for pneumonia therapeutic products. Major players operating in the global pneumonia therapeutics market include GlaxoSmithKline plc., Merck & Co. Inc., and Novartis AG., Sanofi, and Eli Lilly and Company.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.